Bayer is reorganising its Crop Science division in Germany to boost global competitiveness amid rising low-cost generic competition.
Activities in Frankfurt will end by 2028, with R&D centralised in Monheim.
Dormagen production will be streamlined, affecting ~200 jobs.
Bayer aims to focus on innovative crop protection products and explore divestments.